Compare Organon & Co. Common Stock (OGN) vs Viking Holdings Ltd Ordinary Shares (VIK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Viking Holdings Ltd Ordinary Shares — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Viking Holdings Ltd Ordinary Shares trades at $82.22 (market cap $36.70B). The key difference: Viking Holdings Ltd Ordinary Shares is far larger — about 10.1× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Viking Holdings Ltd Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Viking Holdings Ltd Ordinary Shares for 6 Days on average.
| OGN | VIK | |
|---|---|---|
Market Cap | $3.62B | $36.70B |
Volume | 2,892,999 | 2,076,556 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $108.26 |
52-Week Low | $5.70 | $57.08 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.04B | $39.07B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Viking Holdings (VIK) trades at $82.16, up 1.72% on the day, with a bullish technical signal and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue for 2025 reached $6.50 billion, with a net income margin of 19.33%, while analyst consensus is strongly bullish with an 86.66% buy rating and a $107.92 price target. Recent news highlights fleet expansion, a $1 billion share repurchase program, and premium positioning in luxury travel.
VIK presents a compelling growth opportunity driven by strong bookings, expanding fleet, and premium valuations, though risks include execution on capital expenditure and sensitivity to travel disruptions. The stock's current price near key support at $81 suggests potential for upward movement toward resistance levels, supported by positive institutional sentiment and operational cash flow strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Viking Holdings Ltd Ordinary Shares
Viking operates river, ocean, and expedition cruises. Its itineraries focus on destination-based travel across Europe, the Americas, and other regions.
Read more on VIK →
